Research Analysts Issue Forecasts for ALDX FY2028 Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Analysts at Leerink Partnrs lowered their FY2028 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will post earnings per share of $2.50 for the year, down from their previous forecast of $2.55. The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.48) per share.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting analysts' consensus estimates of ($0.25).

Separately, HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

Aldeyra Therapeutics Stock Down 1.4 %

NASDAQ ALDX traded down $0.06 during trading hours on Friday, reaching $4.21. The company's stock had a trading volume of 621,077 shares, compared to its average volume of 490,739. The firm has a fifty day simple moving average of $5.53 and a 200-day simple moving average of $4.60. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics has a 52 week low of $2.43 and a 52 week high of $6.55.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE bought a new stake in Aldeyra Therapeutics in the third quarter valued at $30,000. SG Americas Securities LLC bought a new stake in Aldeyra Therapeutics during the second quarter worth $38,000. Paloma Partners Management Co purchased a new stake in Aldeyra Therapeutics in the 3rd quarter valued at $62,000. Diversified Trust Co bought a new position in Aldeyra Therapeutics during the 2nd quarter valued at $41,000. Finally, King Wealth Management Group boosted its holdings in Aldeyra Therapeutics by 24.5% during the 3rd quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company's stock worth $74,000 after acquiring an additional 2,700 shares during the last quarter. Institutional investors own 59.71% of the company's stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.